Member Info for gadgie

Are they holding onto those 2 million plus Golden Tickets .... Mum's the word

Unusual they alway's offload .... none today nod nod wink wink

Just warming up hang on hold fire !

Oh sorry I thought Avacta were drilling for Oil, honest Guv made me 10% and sold ... What is it that Avacta do then as Terry the Twat said this was a oiler ?

Rampers LOL .... :)

Remarkable trial results from Avacta's tumor targeting drug

https://www.outsourcing-pharma.com/Article/2023/06/22/remarkable-trial-results-from-avacta-s-tumor-targeting-drug

Avacta on ‘verge of a paradigm shift in how chemotherapy is delivered to cancer patients

https://ukinvestormagazine.co.uk/avacta-on-verge-of-a-paradigm-shift-in-how-chemotherapy-is-delivered-to-cancer-patients-shares-surge/

Not you Buddy

Where are u now Twat

Difficult to buy HL ....

Nice place to weather the incoming storms anchor up in the Harbour ..... ( Dow ...FTSE ...NAS ...) Biotec safe bet

Top research GMCC once again thank you

One thing for Sure after Lilly tie in ... all the Major's will no longer be glancing at a distance

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/0edad695-bd3b-40cb-8584-55815a4c98c1

( interesting statement ring a bell ? )

He said the deal’s real value lies in the pipeline of drugs earlier in development, which are trying to improve on the market leaders by making them more lethal to cancer cells but safer to administer. 

https://www.ft.com/content/0edad695-bd3b-40cb-8584-55815a4c98c1

What is Affyxell about to be Valued at ?

AFX-001

AFX-002

http://affyxell.com/pipeline/pipeline.php

https://avacta.com/therapeutics/pipeline/

Header Say's it all ..... interesting to see amount spent on Affimer .... Research costs relating to new diagnostic tests in the Diagnostics Division wonder what we got coming test wise ?

Validated / Paradigm shift .................

Bit like xmas eve waiting for Santa :)

N the financial year to 31 December 2021, Launch Diagnostics generated revenues related to sales of products for COVID-19 testing and products unrelated to COVID-19. Launch Diagnostics’ core, non-COVID-19 revenues were £14.17 million and total revenues were £32.75 million with total Adjusted EBITDA of £8.52 million[3] and a profit before tax of £9.36 million. As of 31 December 2021, Launch Diagnostics had net assets of £17.0 million. Launch Diagnostics’ FY21 revenues were geographically split between the UK and France and the Benelux region, with the former accounting for £23.85 million and the latter £8.9 million.

During FY20 and FY21, Launch Diagnostics’ revenue growth was driven primarily by its COVID-19 testing products and, whilst these revenues have been discounted by 80% in Avacta’s valuation of the business, the Company believes there is still potential for some sustainable ongoing COVID test revenues from symptomatic testing in hospitals. During the past two years, the focus on COVID-19 testing saw Launch Diagnostics’ sales of non-COVID-19 products fall from £18.51 million in FY19 to £14.17 million in FY21, but this business is now increasing as customers return to normal purchasing cycles.

Interested in performance mid year both Coris and Launch Diagnostics any thoughts on potential revenue ....will we get a re rating based on income ?

We have Excellent working relationships / partnerships with LG and indeed Daewoong both looking at Major Expansion will the Big Boy's allow this to potentially go to Korea HMMMMMM

all this ****e about funding unreal ..... we will get a licensing deal for our ground breaking game changer .......we are on every majors radar end !